文献速递临床免疫临床生化

新型酶免疫分析法测定高唾液酸化及岩藻糖化人α1-酸性糖蛋白作为肿瘤发生生物标志物

A new enzyme immunoassay for the determination of highly sialylated and fucosylated human α1-acid glycoprotein as a biomarker of tumorigenesis.
PubMed 文献 · Clin Chim Acta · 2017-12-21

本研究开发了一种基于抗AGP抗体和岩藻糖结合凝集素AAL的酶免疫分析法,用于定量检测血清中岩藻糖化AGP。该方法在癌症患者和健康对照样本中均表现良好,且岩藻糖化AGP在化疗患者中与癌症进展、预后及早期疗效评估相关,在抗PD-1抗体免疫治疗患者中亦显示相关性。结论认为α1,3岩藻糖化AGP是癌症发生、进展和治疗反应的潜在生物标志物。

要点

  • 新型EIA可定量检测血清岩藻糖化AGP,性能良好。
  • 岩藻糖化AGP与癌症进展、预后及化疗早期反应相关。
  • 岩藻糖化AGP在抗PD-1免疫治疗患者中亦显示相关性。

核心结论

  • α1,3岩藻糖化AGP是癌症发生、进展和治疗反应的潜在生物标志物。

研究设计与样本

  • 开发了采用抗AGP抗体和岩藻糖结合凝集素AAL的酶免疫分析法,并改进了样本处理和抗体制备。

主要发现

  • 该方法在所有测试的癌症患者和健康对照样本中均能良好地测定岩藻糖化AGP含量。
  • 在化疗癌症患者中,岩藻糖化AGP与癌症进展或预后相关,并可用于早期评估临床反应和治疗结果。
  • 在接受抗PD-1抗体免疫治疗的患者中,岩藻糖化AGP也显示相关性。

临床怎么用

  • 岩藻糖化AGP或可作为癌症进展、预后及治疗反应评估的辅助生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Upon initiation and progression of cancer, α1-acid glycoprotein (AGP) possessing highly sialylated and fucosylated glycans appears in the serum, and recently has attracted a great deal of attention, as a potential biomarker of tumorigenesis in humans. METHODS: To establish a rapid and precise method for the quantitative assay of fucosylated AGP in serum samples, we developed an enzyme immunoassay (EIA) bearing an anti-AGP antibody and a fucose-binding lectin, Aleuria aurantia (AAL) with additional endeavor to improved sample handling, and antibody preparations. RESULTS: The amounts of fucosylated AGP could be determined by the present method with a good performance feature in all tested samples from both cancer patients and healthy controls. From cancer patients under chemotherapy we show that fucosylated AGP could be a clinically relevant biomarker for cancer progression or prognosis as well as for an early assessment of clinical response and treatment outcomes. Furthermore, in a different setting, fucosylated AGP also showed relevance in patients who received immunotherapy with an anti-programmed cell death-1 (PD-1) antibody. CONCLUSIONS: α1,3fucosylated AGP is a potential biomarker of cancer initiation, progression and response to treatment in cancer patients.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Yazawa S, Yokobori T, Kaira K, et al. A new enzyme immunoassay for the determination of highly sialylated and fucosylated human α1-acid glycoprotein as a biomarker of tumorigenesis. Clin Chim Acta. 2017. PMID: 29274330. doi:10.1016/j.cca.2017.12.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。